JP2008521916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008521916A5 JP2008521916A5 JP2007544475A JP2007544475A JP2008521916A5 JP 2008521916 A5 JP2008521916 A5 JP 2008521916A5 JP 2007544475 A JP2007544475 A JP 2007544475A JP 2007544475 A JP2007544475 A JP 2007544475A JP 2008521916 A5 JP2008521916 A5 JP 2008521916A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- pharmaceutical composition
- composition according
- immunodeficiency
- immunomodulatory compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 22
- 208000029462 Immunodeficiency disease Diseases 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 11
- 230000002519 immonomodulatory effect Effects 0.000 claims 11
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims 6
- 125000004648 C2-C8 alkenyl group Chemical group 0.000 claims 6
- 125000004649 C2-C8 alkynyl group Chemical group 0.000 claims 6
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 4
- 230000007812 deficiency Effects 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 208000011580 syndromic disease Diseases 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 2
- 208000008190 Agammaglobulinemia Diseases 0.000 claims 2
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims 2
- 206010020983 Hypogammaglobulinaemia Diseases 0.000 claims 2
- 206010061598 Immunodeficiency Diseases 0.000 claims 2
- 208000031951 Primary immunodeficiency Diseases 0.000 claims 2
- 239000013543 active substance Substances 0.000 claims 2
- 239000003443 antiviral agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 230000007813 immunodeficiency Effects 0.000 claims 2
- 230000000091 immunopotentiator Effects 0.000 claims 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 1
- 208000010543 22q11.2 deletion syndrome Diseases 0.000 claims 1
- YLDCUKJMEKGGFI-QCSRICIXSA-N 4-acetamidobenzoic acid;9-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3h-purin-6-one;1-(dimethylamino)propan-2-ol Chemical compound CC(O)CN(C)C.CC(O)CN(C)C.CC(O)CN(C)C.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.CC(=O)NC1=CC=C(C(O)=O)C=C1.O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(NC=NC2=O)=C2N=C1 YLDCUKJMEKGGFI-QCSRICIXSA-N 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 201000010717 Bruton-type agammaglobulinemia Diseases 0.000 claims 1
- 229930186147 Cephalosporin Natural products 0.000 claims 1
- 206010010099 Combined immunodeficiency Diseases 0.000 claims 1
- 208000000398 DiGeorge Syndrome Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000007924 IgA Deficiency Diseases 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 102000015696 Interleukins Human genes 0.000 claims 1
- 108010063738 Interleukins Proteins 0.000 claims 1
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical group C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 claims 1
- 229930182555 Penicillin Natural products 0.000 claims 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 206010054979 Secondary immunodeficiency Diseases 0.000 claims 1
- 206010039915 Selective IgA immunodeficiency Diseases 0.000 claims 1
- 206010057863 Selective IgG subclass deficiency Diseases 0.000 claims 1
- 208000012827 T-B+ severe combined immunodeficiency due to gamma chain deficiency Diseases 0.000 claims 1
- 206010043189 Telangiectasia Diseases 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 102000040945 Transcription factor Human genes 0.000 claims 1
- 108091023040 Transcription factor Proteins 0.000 claims 1
- 208000023940 X-Linked Combined Immunodeficiency disease Diseases 0.000 claims 1
- 208000016349 X-linked agammaglobulinemia Diseases 0.000 claims 1
- 201000007146 X-linked severe combined immunodeficiency Diseases 0.000 claims 1
- 229960004150 aciclovir Drugs 0.000 claims 1
- MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 claims 1
- 201000009628 adenosine deaminase deficiency Diseases 0.000 claims 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 1
- 229960003805 amantadine Drugs 0.000 claims 1
- 229960000723 ampicillin Drugs 0.000 claims 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims 1
- 239000003242 anti bacterial agent Substances 0.000 claims 1
- 208000036556 autosomal recessive T cell-negative B cell-negative NK cell-negative due to adenosine deaminase deficiency severe combined immunodeficiency Diseases 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 229940124587 cephalosporin Drugs 0.000 claims 1
- 150000001780 cephalosporins Chemical class 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 230000007850 degeneration Effects 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 229960003276 erythromycin Drugs 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000002163 immunogen Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 201000007156 immunoglobulin alpha deficiency Diseases 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 229960000318 kanamycin Drugs 0.000 claims 1
- 229930027917 kanamycin Natural products 0.000 claims 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 claims 1
- 229930182823 kanamycin A Natural products 0.000 claims 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 1
- 229960001614 levamisole Drugs 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940049954 penicillin Drugs 0.000 claims 1
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- 229960000888 rimantadine Drugs 0.000 claims 1
- 208000029138 selective IgA deficiency disease Diseases 0.000 claims 1
- 229960005322 streptomycin Drugs 0.000 claims 1
- 208000009056 telangiectasis Diseases 0.000 claims 1
- 229960002180 tetracycline Drugs 0.000 claims 1
- 229930101283 tetracycline Natural products 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- 208000008732 thymoma Diseases 0.000 claims 1
- 239000000724 thymus hormone Substances 0.000 claims 1
- 230000001052 transient effect Effects 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
- 0 C*(*c1c(CC(CI=C)*(C)(C)*)cccc1*)C(*)(CCC(*1)=O)C1=O Chemical compound C*(*c1c(CC(CI=C)*(C)(C)*)cccc1*)C(*)(CCC(*1)=O)C1=O 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US63187004P | 2004-12-01 | 2004-12-01 | |
| US60/631,870 | 2004-12-01 | ||
| PCT/US2005/043360 WO2006060507A2 (en) | 2004-12-01 | 2005-11-30 | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012176776A Division JP2012255009A (ja) | 2004-12-01 | 2012-08-09 | 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2008521916A JP2008521916A (ja) | 2008-06-26 |
| JP2008521916A5 true JP2008521916A5 (https=) | 2009-01-22 |
| JP5775245B2 JP5775245B2 (ja) | 2015-09-09 |
Family
ID=36143704
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007544475A Expired - Fee Related JP5775245B2 (ja) | 2004-12-01 | 2005-11-30 | 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 |
| JP2012176776A Pending JP2012255009A (ja) | 2004-12-01 | 2012-08-09 | 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012176776A Pending JP2012255009A (ja) | 2004-12-01 | 2012-08-09 | 免疫不全障害の治療のために免疫調節化合物を用いる方法及び組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US8394832B2 (https=) |
| EP (1) | EP1924250B1 (https=) |
| JP (2) | JP5775245B2 (https=) |
| KR (1) | KR20070090227A (https=) |
| CN (1) | CN101111234A (https=) |
| AU (1) | AU2005311888A1 (https=) |
| BR (1) | BRPI0518793A2 (https=) |
| CA (1) | CA2588990A1 (https=) |
| IL (1) | IL183537A0 (https=) |
| MX (1) | MX2007006439A (https=) |
| NZ (1) | NZ555886A (https=) |
| WO (1) | WO2006060507A2 (https=) |
| ZA (1) | ZA200704964B (https=) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2009010082A (es) | 2007-03-20 | 2009-10-19 | Celgene Corp | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
| CA2704710C (en) | 2007-09-26 | 2016-02-02 | Celgene Corporation | 6-, 7-, or 8-substituted quinazolinone derivatives and compositions comprising the same |
| WO2009085234A2 (en) | 2007-12-20 | 2009-07-09 | Signal Pharmaceuticals, Inc. | Use of micro-rna as a biomarker of immunomodulatory drug activity |
| WO2009105256A2 (en) * | 2008-02-20 | 2009-08-27 | Celgene Corporation | Method of treating cancer by administering an immunomodulatory compound in combination with a cd40 antibody or cd40 ligand |
| US20090298882A1 (en) * | 2008-05-13 | 2009-12-03 | Muller George W | Thioxoisoindoline compounds and compositions comprising and methods of using the same |
| US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
| PT2358697E (pt) | 2008-10-29 | 2016-02-03 | Celgene Corp | Compostos de isoindolina para utilização no tratamento do cancro |
| US20120053159A1 (en) | 2009-02-11 | 2012-03-01 | Muller George W | Isotopologues of lenalidomide |
| EP3489352A1 (en) | 2009-03-25 | 2019-05-29 | Celularity, Inc. | Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds |
| CN103800906B (zh) | 2009-03-25 | 2017-09-22 | 德克萨斯大学系统董事会 | 用于刺激哺乳动物对病原体的先天免疫抵抗力的组合物 |
| EP2436387B1 (en) | 2009-05-25 | 2018-07-25 | Celgene Corporation | Pharmaceutical composition comprising crbn for use in treating a disease of the cerebral cortex |
| CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
| BR112012015129A2 (pt) | 2009-12-22 | 2019-09-24 | Celgene Corp | "composto, composição farmacêutica e método para tratar, controlar ou prevenir uma doença ou distúrbio" |
| MX337566B (es) | 2010-01-05 | 2016-03-10 | Celgene Corp | Combinación de un compuesto inmunomodulador y una artemisinina o un derivado de ésta para tratar cáncer. |
| PL3202460T3 (pl) | 2010-02-11 | 2019-12-31 | Celgene Corporation | Pochodne arylometoksyizoindoliny i zawierające je kompozycje oraz sposoby ich zastosowania |
| WO2012079075A1 (en) | 2010-12-10 | 2012-06-14 | Concert Pharmaceuticals, Inc. | Deuterated phthalimide derivatives |
| EP2663549B1 (en) | 2011-01-10 | 2018-03-14 | Celgene Corporation | Phenethylsulfone isoindoline derivatives as inhibitors of pde 4 and/or cytokines |
| DK2683708T3 (da) | 2011-03-11 | 2018-01-29 | Celgene Corp | Faste former af 3-(5-amino-2-methyl-4-oxo-4h-quinazolin-3-yl)-piperidin-2,6-dion og farmaceutiske sammensætninger og anvendelser deraf |
| EP2699091B1 (en) | 2011-03-28 | 2017-06-21 | DeuteRx, LLC | 2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds |
| WO2012145309A1 (en) | 2011-04-18 | 2012-10-26 | Celgene Corporation | Biomarkers for the treatment of multiple myeloma |
| AU2012249491B2 (en) | 2011-04-29 | 2016-12-15 | Celgene Corporation | Methods for the treatment of cancer and inflammatory diseases using cereblon as a predictor |
| US20140221427A1 (en) | 2011-06-22 | 2014-08-07 | Celgene Corporation | Isotopologues of pomalidomide |
| RS60415B1 (sr) | 2011-12-27 | 2020-07-31 | Amgen (Europe) GmbH | Formulacije (+)-2-[1-(3-etoksi-4-metoksi-fenil)-2-metansulfonil-etil]-4-acetil aminoizoindolin-1,3-diona |
| WO2013130849A1 (en) | 2012-02-29 | 2013-09-06 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| US9249093B2 (en) | 2012-04-20 | 2016-02-02 | Concert Pharmaceuticals, Inc. | Deuterated rigosertib |
| ES2872967T3 (es) | 2012-06-29 | 2021-11-03 | Celgene Corp | Métodos para determinar la eficacia de fármacos usando IKZF3 (AIOLOS) |
| US9587281B2 (en) | 2012-08-14 | 2017-03-07 | Celgene Corporation | Cereblon isoforms and their use as biomarkers for therapeutic treatment |
| EP2922838B1 (en) | 2012-10-22 | 2018-03-14 | Concert Pharmaceuticals Inc. | Solid forms of {s-3-(4-amino-1-oxo-isoindolin-2-yl)(piperidine-3,4,4,5,5-d5)-2,6-dione} . |
| WO2014110322A2 (en) | 2013-01-11 | 2014-07-17 | Concert Pharmaceuticals, Inc. | Substituted dioxopiperidinyl phthalimide derivatives |
| JP6359563B2 (ja) | 2013-01-14 | 2018-07-18 | デュートルクス・リミテッド・ライアビリティ・カンパニーＤｅｕｔｅＲｘ， ＬＬＣ | ３−（５置換−４−オキソキナゾリン−３（４ｈ）−イル）−３−ジュウテロピペリジン−２，６−ジオン誘導体 |
| BR112015025252A2 (pt) | 2013-04-02 | 2017-07-18 | Celgene Corp | métodos e composições usando 4-amino-2-(2,6-dioxo-piperidina-3-il)-isoindolina-1,3-diona para tratamento e gestão de cânceres de sistema nervoso central |
| EP2815749A1 (en) | 2013-06-20 | 2014-12-24 | IP Gesellschaft für Management mbH | Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern |
| EP3827836A1 (en) | 2014-06-27 | 2021-06-02 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| WO2016044839A2 (en) | 2014-09-19 | 2016-03-24 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds |
| WO2017117118A1 (en) | 2015-12-28 | 2017-07-06 | Celgene Corporation | Compositions and methods for inducing conformational changes in cereblon and other e3 ubiquitin ligases |
| TWI793151B (zh) | 2017-08-23 | 2023-02-21 | 瑞士商諾華公司 | 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途 |
| BR112020017053A2 (pt) | 2018-02-21 | 2020-12-15 | Celgene Corporation | Anticorpos que se ligam ao bcma e usos dos mesmos |
| BR122022012697B1 (pt) | 2018-07-10 | 2023-04-04 | Novartis Ag | Usos de derivados de 3-(5-hidróxi-1-oxoisoindolin-2-il)piperidina-2,6- diona, e kit |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| US20030013649A1 (en) * | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| US7521463B2 (en) * | 2000-07-31 | 2009-04-21 | University Of Maryland, Baltimore | Immunomodulatory compounds |
| US7091353B2 (en) * | 2000-12-27 | 2006-08-15 | Celgene Corporation | Isoindole-imide compounds, compositions, and uses thereof |
| JP2004083564A (ja) * | 2002-05-31 | 2004-03-18 | Takeda Chem Ind Ltd | 新規スクリーニング方法 |
| US7119713B2 (en) | 2002-06-27 | 2006-10-10 | Elster Electricity, Llc | Dynamic self-configuring metering network |
| US7563810B2 (en) * | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
| CA2560221C (en) * | 2004-03-22 | 2010-12-07 | Celgene Corporation | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
| MX2009010082A (es) * | 2007-03-20 | 2009-10-19 | Celgene Corp | Derivados y composiciones que comprenden isoindolina 4'-o-sustituida y metodos para utilizar la misma. |
-
2005
- 2005-11-30 NZ NZ555886A patent/NZ555886A/en not_active IP Right Cessation
- 2005-11-30 MX MX2007006439A patent/MX2007006439A/es not_active Application Discontinuation
- 2005-11-30 JP JP2007544475A patent/JP5775245B2/ja not_active Expired - Fee Related
- 2005-11-30 EP EP05852555.1A patent/EP1924250B1/en not_active Expired - Lifetime
- 2005-11-30 AU AU2005311888A patent/AU2005311888A1/en not_active Abandoned
- 2005-11-30 CN CNA2005800473644A patent/CN101111234A/zh active Pending
- 2005-11-30 BR BRPI0518793-1A patent/BRPI0518793A2/pt not_active IP Right Cessation
- 2005-11-30 ZA ZA200704964A patent/ZA200704964B/xx unknown
- 2005-11-30 CA CA002588990A patent/CA2588990A1/en not_active Abandoned
- 2005-11-30 WO PCT/US2005/043360 patent/WO2006060507A2/en not_active Ceased
- 2005-11-30 US US11/289,723 patent/US8394832B2/en not_active Expired - Fee Related
- 2005-11-30 KR KR1020077015076A patent/KR20070090227A/ko not_active Withdrawn
-
2007
- 2007-05-29 IL IL183537A patent/IL183537A0/en unknown
-
2012
- 2012-08-09 JP JP2012176776A patent/JP2012255009A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008521916A5 (https=) | ||
| EP1924250B1 (en) | Methods and compositions comprising immunomodulatory compounds for use for the treatment of immunodeficiency disorders | |
| CN100584331C (zh) | 免疫调节化合物在制备用于治疗、控制或预防骨髓增生性疾病的药物中的应用 | |
| WO2006069155A3 (en) | Inhibitors of protein arginine methyl transferases | |
| CN101583359B (zh) | 3-(4-氨基-1-氧代-1,3-二氢-异吲哚-2-基)-哌啶-2,6-二酮在套细胞淋巴瘤治疗中的用途 | |
| CN115068484A (zh) | 免疫相关和炎性疾病的治疗 | |
| JP2018527366A (ja) | ＨＩＶを処置するためのｔｏｌｌ様レセプターのモジュレーター | |
| CA2672000A1 (en) | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma | |
| JP2005530784A5 (https=) | ||
| KR20060096415A (ko) | Ｃ형 간염 바이러스에 의한 감염증을 치료하기 위해투여하는 ｔｌｒ７ 리간드 및 이의 전구약물 | |
| JP2010540424A5 (https=) | ||
| JP2007045839A5 (https=) | ||
| JP2004511518A5 (https=) | ||
| JP2006509000A5 (https=) | ||
| JP2004525179A5 (https=) | ||
| RU2008144584A (ru) | 4,5-дигидро-[1,2,4]триазоло[4,3-f]птеридины в качестве ингибиторов протеинкиназы plk1 для лечения пролиферативных заболеваний | |
| JPWO2010123049A1 (ja) | 癌治療のための選択的ｅｐ４受容体拮抗物質 | |
| JP2023528722A (ja) | サイトカインストーム症候群及び関連疾患を治療する方法 | |
| RU2015141591A (ru) | Ингибиторы тирозинкиназы брутона | |
| JP2013512195A5 (https=) | ||
| CN1984657B (zh) | 用于治疗和控制骨髓增生性疾病的包含免疫调节化合物的组合物和使用方法 | |
| RU2002110111A (ru) | Замещенные пирролы в качестве антипролиферативных средств для лечения рака | |
| HK1161973A (en) | Methods and compositions using 4-(amino)-2-(2,6-dioxo(3-piperidyl))-isoindoline-1,3-dione in treatment and control of amyloidosis | |
| HK1104968B (en) | Use of immunomodulatory compounds in the manufacture of a medicament for the treatment and management of cancers and other diseases, and compositions thereof | |
| HK1166010A (en) | Method and composition for treatment of multiple myeloma |